BELLUS Health Inc.
BLU.TO
Toronto Stock Exchange19.48
CAD
-0.02
- -
BELLUS Health Inc.
BLU.TO
(Toronto Stock Exchange)
Recent
price
19.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- BELLUS Health Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for refractory chronic cough and other cough hypersensitivity indications, including its lead product candidate camlipixant (BLU-5937), a potent and highly selective P2X3 receptor antagonist in Phase 3 clinical trials for refractory chronic cough with topline data expected in late 2024 and 2025 and potential regulatory approval and launch in 2026; the company previously advanced BLU-5937 for chronic pruritus. Founded in 1993 and headquartered in Laval, Quebec, Canada, BELLUS Health focuses on high unmet medical needs in respiratory conditions, targeting patients unresponsive to existing treatments across North America and global markets. In June 2023, GSK plc completed its $2.0 billion acquisition of BELLUS Health, integrating the company as a subsidiary to leverage GSK's respiratory expertise, R&D, manufacturing, and commercialization capabilities, with camlipixant expected to contribute to GSK's pipeline growth and be accretive to adjusted EPS from 2027 onward.